{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:56:43Z","timestamp":1781765803913,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004507","name":"Central Drug Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.biopha.2021.112390","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T14:19:05Z","timestamp":1637849945000},"page":"112390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discontinuation of PTH therapy amplifies bone loss by increasing oxidative stress: An event ameliorated by sequential IL-17 neutralizing antibody therapy"],"prefix":"10.1016","volume":"145","author":[{"given":"Krishna Bhan","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu","family":"Khanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112390_bib1","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","article-title":"Mortality after osteoporotic fractures","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.biopha.2021.112390_bib3","first-page":"391","article-title":"The role of cytokines in postmenopausal osteoporosis","volume":"66","author":"Brincat","year":"2014","journal-title":"Minerva Ginecol."},{"key":"10.1016\/j.biopha.2021.112390_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1079\/PNS2002160","article-title":"Plenary lecture: strategies for skeletal health in the elderly","volume":"61","author":"Eastell","year":"2002","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.biopha.2021.112390_bib5","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: an inflammatory tale","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2021.112390_bib6","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study*","volume":"16","author":"Dempster","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"Mcclung","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2021.112390_bib8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112390_bib9","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3390\/jcm9113439","article-title":"Anti-sclerostin antibodies in osteoporosis and other bone diseases","volume":"9","author":"Fabre","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2021.112390_bib10","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study*","volume":"16","author":"Dempster","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.112390_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/endo-110-2-506","article-title":"Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration","volume":"110","author":"Tam","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2021.112390_bib13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling\u2014mechanistic insights and therapeutic prospects","volume":"11","author":"Cheloha","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112390_bib14","first-page":"S26","article-title":"The effect of 1 year of alendronate following 1 year of PTH 1-84: Second year results from the PTH and alendronate (PaTH) trial","volume":"19","author":"Black","year":"2004","journal-title":"J. BONE Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled european study of forsteo (EUROFORS)*","volume":"24","author":"Eastell","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19877994","article-title":"Update on the safety and efficacy of teriparatide in the treatment of osteoporosis","volume":"11","author":"Minisola","year":"2019","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.biopha.2021.112390_bib17","article-title":"Cyclic treatment regime rescues pth withdrawal-induced bone loss and microarchitecture deterioration","volume":"27","author":"Tseng","year":"2017","journal-title":"Univ. Pa. Orthop. J."},{"key":"10.1016\/j.biopha.2021.112390_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11914-014-0237-9","article-title":"Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches","volume":"12","author":"Cosman","year":"2014","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.biopha.2021.112390_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112390_bib20","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate1","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.112390_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2014.01.008","article-title":"A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment","volume":"61","author":"Altman","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bone.2017.10.021","article-title":"The effect of switching from teriparatide to anti-RANKL antibody on cancellous and cortical bone in ovariectomized mice","volume":"107","author":"Omiya","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib23","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.112390_bib24","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/boneres.2016.55","article-title":"Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone Res."},{"key":"10.1016\/j.biopha.2021.112390_bib25","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by Anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared With Anti-RANKL and Anti-TNF-\u03b1 antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bone.2017.09.010","article-title":"Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17\/N-cadherin mediated disruption of PTHR1\/LRP-6 interaction","volume":"105","author":"Mansoori","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib27","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1074\/jbc.M116.764779","article-title":"Interleukin 27 (IL-27) alleviates bone loss in estrogen-deficient conditions by induction of early growth response-2 gene","volume":"292","author":"Shukla","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2021.112390_bib28","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with Anti-RANKL and Anti-TNF-\u03b1 antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bone.2017.09.010","article-title":"Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17\/N-cadherin mediated disruption of PTHR1\/LRP-6 interaction","volume":"105","author":"Mansoori","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib30","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00198-017-4012-5","article-title":"Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model","volume":"28","author":"Dixit","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib32","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00198-017-4012-5","article-title":"Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model","volume":"28","author":"Dixit","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib33","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1074\/jbc.M116.764779","article-title":"Interleukin 27 (IL-27) alleviates bone loss in estrogen-deficient conditions by induction of early growth response-2 gene","volume":"292","author":"Shukla","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2021.112390_bib34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by Anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with Anti-RANKL and Anti-TNF-\u03b1 antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bone.2019.03.010","article-title":"Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: a comparative study with human parathyroid hormone","volume":"123","author":"Pal","year":"2019","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.biopha.2021.112390_bib36","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00198-017-4012-5","article-title":"Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model","volume":"28","author":"Dixit","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.biopha.2021.112390_bib37","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/cddis.2014.4","article-title":"miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation","volume":"5","author":"Kureel","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2021.112390_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bone.2017.09.010","article-title":"Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17\/N-cadherin mediated disruption of PTHR1\/LRP-6 interaction","volume":"105","author":"Mansoori","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib39","article-title":"Conflict of Interest","author":"Tyagi","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2021.112390_bib40","first-page":"4307","article-title":"Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2021.112390_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40816-020-00190-z","article-title":"Self-emulsifying formulation of Spinacia oleracea reduces the dose and escalates bioavailability of bioactive compounds to accelerate fracture repair in rats","volume":"6","author":"Trivedi","year":"2020","journal-title":"Clin. Phytosci."},{"key":"10.1016\/j.biopha.2021.112390_bib42","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00198-017-4012-5","article-title":"Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model","volume":"28","author":"Dixit","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib43","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","article-title":"A systematic review of factors affecting medication adherence among patients with osteoporosis","volume":"29","author":"Yeam","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib44","first-page":"S26","article-title":"The effect of 1 year of alendronate following 1 year of PTH 1-84: Second year results from the PTH and alendronate (PaTH) trial","volume":"Vol. 19","author":"Black","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib45","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.112390_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.112390_bib47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","article-title":"Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy","volume":"19","author":"Cosman","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib48","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","article-title":"Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy","volume":"19","author":"Cosman","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib49","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.112390_bib50","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.112390_bib51","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jbmr.1853","article-title":"Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene","volume":"28","author":"Cosman","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.112390_bib53","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with Anti-RANKL and Anti-TNF-\u03b1 antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2021.112390_bib54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bone.2017.09.010","article-title":"Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17\/N-cadherin mediated disruption of PTHR1\/LRP-6 interaction","volume":"105","author":"Mansoori","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib55","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.bone.2006.11.027","article-title":"PINP: A serum biomarker of bone formation in the rat","volume":"40","author":"Hale","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2021.112390_bib56","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.onc.1208385","article-title":"Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS","volume":"24","author":"Liu","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2021.112390_bib57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cell.2006.03.046","article-title":"A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span","volume":"125","author":"Lehtinen","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.112390_bib58","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.4049\/jimmunol.1500849","article-title":"Foxo1 Is a T Cell\u2013Intrinsic Inhibitor of the ROR\u03b3t-Th17 Program","volume":"195","author":"Lain\u00e9","year":"2015","journal-title":"J. Immunol."},{"issue":"1Supplement","key":"10.1016\/j.biopha.2021.112390_bib59","doi-asserted-by":"crossref","first-page":"130.4","DOI":"10.4049\/jimmunol.194.Supp.130.4","article-title":"ATF4 reprograms T cell metabolism in response to the environmental stress and is required for Th1 immune responses (IRM9P. 459)","volume":"194","author":"Xia","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112390_bib60","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00198-017-4012-5","article-title":"Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model","volume":"28","author":"Dixit","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2021.112390_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007583","article-title":"Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone","volume":"4","author":"Yu","year":"2009","journal-title":"PLoS One"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:25:58Z","timestamp":1781763958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":61,"alternative-id":["S0753332221011768"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112390","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of PTH therapy amplifies bone loss by increasing oxidative stress: An event ameliorated by sequential IL-17 neutralizing antibody therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112390"}}